Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14656508 | 0.89 | FGFR1 (0.61) | FGFR1HTT | |
| Hydrochloric Acid SCHEMBL14656318 | 0.88 | FGFR1 (0.60) | FGFR1HTT | |
| Bicarbonate SCHEMBL2334509 | 0.86 | HTT (0.85) | FGFR1HTT | |
| SCHEMBL29993159 | 0.86 | FGFR1 (0.74) | FGFR1HTTPDE4APDE4BPDE4C | |
| SCHEMBL20604030 | 0.86 | FGFR1 (0.74) | FGFR1HTTPDE4APDE4BPDE4C | |
| SCHEMBL7383547 | 0.86 | FGFR1 (0.72) | FGFR1HTTPDE4APDE4BPDE4C | |
| SCHEMBL1354830 | 0.84 | FGFR1 (0.71) | FGFR1HTT | |
| SCHEMBL29526516 | 0.84 | FGFR1 (0.71) | FGFR1HTT | |
| SCHEMBL3419279 | 0.84 | HTT (0.88) | FGFR1HTT | |
| SCHEMBL30402227 | 0.84 | HTT (0.88) | FGFR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2074088-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008045371-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045371-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | HNMT, HRH4, HRH3 | FGFR1 2424/4885HTT 378/4885PDE4A 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.